Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Achillion Pharmaceuticals
About
A biopharmaceutical company dedicated to transforming the lives of patients and families affected by disorders of the complement system.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series Unknown
- Last Funding Money Raised
- $41M
- Industries
- Biotechnology,Health Care,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 1998
- Number Of Employee
- 51 - 100
- Operating Status
- Active
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 28, 2002 | Series Unknown | $41M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Advent International
|
— | Series Unknown |
|
|
— | Series Unknown |
